Bernstein initiated coverage of Summit Therapeutics (SMMT) with an Underperform rating and $7.70 price target
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- 3 Best Stocks to Buy This Week, According to Analysts – May 18-May 22
- Unusually active option classes on open May 6th
- Tyler Van Buren Reiterates Buy on Summit Therapeutics, Citing Stable Long-Term Sales Outlook and Attractive Risk/Reward Despite Higher Future OpEx
- Summit Therapeutics price target lowered to $23 from $30 at H.C. Wainwright
- Summit Therapeutics Flags Significant Going-Concern Risk Amid Cash Shortfall and Uncertain Financing